Market revenue in 2021 | USD 13.3 million |
Market revenue in 2030 | USD 113.7 million |
Growth rate | 26.9% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 33.08% in 2021. Horizon Databook has segmented the India non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
India has a similar incidence and prevalence of NAFLD as the rest of the world; it is most common in people between the ages of 30 and 50. NASH would probably be present in 5% of those with NAFLD diagnoses.
It has been shown that NAFLD, sometimes known as "lean" NAFLD, can develop in people who are not obese or who do not have diabetes in India. Some of the major players in India are focusing on collaborations for drug discovery using biomarkers.
This is expected to drive the growth of drug discovery segment in this country. Key market players along with the Indian government are focusing on collaborations for advancing biomarker testing and offering products to address the unmet need of NASH patients.
Horizon Databook provides a detailed overview of country-level data and insights on the India non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into India non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account